AKTing on XPO1 inhibition in AML

Stefanie Göllner¹, Carsten Müller-Tidow^{2

3

4}

Affiliations

¹ Department of Medicine V - Hematology, Oncology and Rheumatology, University Hospital Heidelberg, Heidelberg, Germany. stefanie.goellner@med.uni-heidelberg.de.
² Department of Medicine V - Hematology, Oncology and Rheumatology, University Hospital Heidelberg, Heidelberg, Germany. carsten.mueller-tidow@med.uni-heidelberg.de.
³ Molecular Medicine Partnership Unit, European Molecular Biology Laboratory and University of Heidelberg, Heidelberg, Germany. carsten.mueller-tidow@med.uni-heidelberg.de.
⁴ National Center for Tumor Diseases, Heidelberg, Germany. carsten.mueller-tidow@med.uni-heidelberg.de.

Comment

Stefanie Göllner et al. Nat Cancer. 2022 Jul.

. 2022 Jul;3(7):787-789.

doi: 10.1038/s43018-022-00395-w.

Stefanie Göllner¹, Carsten Müller-Tidow^{2

3

4}

¹ Department of Medicine V - Hematology, Oncology and Rheumatology, University Hospital Heidelberg, Heidelberg, Germany. stefanie.goellner@med.uni-heidelberg.de.
² Department of Medicine V - Hematology, Oncology and Rheumatology, University Hospital Heidelberg, Heidelberg, Germany. carsten.mueller-tidow@med.uni-heidelberg.de.
³ Molecular Medicine Partnership Unit, European Molecular Biology Laboratory and University of Heidelberg, Heidelberg, Germany. carsten.mueller-tidow@med.uni-heidelberg.de.
⁴ National Center for Tumor Diseases, Heidelberg, Germany. carsten.mueller-tidow@med.uni-heidelberg.de.

No abstract available

Comment on

P2RY2-AKT activation is a therapeutically actionable consequence of XPO1 inhibition in acute myeloid leukemia.
Lin KH, Rutter JC, Xie A, Killarney ST, Vaganay C, Benaksas C, Ling F, Sodaro G, Meslin PA, Bassil CF, Fenouille N, Hoj J, Washart R, Ang HX, Cerda-Smith C, Chaintreuil P, Jacquel A, Auberger P, Forget A, Itzykson R, Lu M, Lin J, Pierobon M, Sheng Z, Li X, Chilkoti A, Owzar K, Rizzieri DA, Pardee TS, Benajiba L, Petricoin E, Puissant A, Wood KC. Lin KH, et al. Nat Cancer. 2022 Jul;3(7):837-851. doi: 10.1038/s43018-022-00394-x. Epub 2022 Jun 6. Nat Cancer. 2022. PMID: 35668193 Free PMC article.

1. Hutten, S. & Kehlenbach, R. H. Trends Cell Biol. 17, 193–201 (2007). - DOI
1. Tan, D. S., Bedard, P. L., Kuruvilla, J., Siu, L. L. & Razak, A. R. Cancer Discov. 4, 527–537 (2014). - DOI
1. Kojima, K. et al. Blood 121, 4166–4174 (2013). - DOI
1. Taylor, J. et al. Cancer Discov. 9, 1452–1467 (2019). - DOI
1. Lin, K. H. et al. Nat. Cancer https://doi.org/10.1038/s43018-022-00394-x (2022). - DOI - PubMed